Fibrinogen, b43-63
ARPAKAAATQKKVERKAPDA-acid
Description
Application Data
Description
-
Fibrinogen b43-63 Human is derived from Fibrinogen which is highly abundant blood protein involved in fibrin clot formation, haemostasis, and inflammatory responses.
Application Data
-
Data Sheet Material Safety Data Sheet (MSDS)Catalogue number crb1000342 Molecular Weight 2107.42 Sequence (one letter code) ARPAKAAATQKKVERKAPDA-acid
Sequence (three letter code) H-Ala-Arg-Pro-Ala-Lys-Ala-Ala-Ala-Thr-Gln-Lys-Lys-Val-Glu-Arg-Lys-Ala-Pro-Asp-Ala-OH
Purity >95% References Riedel et al (2010) Fibrinopeptides A and B release in the process of surface fibrin formation. Blood 117(5) 1700 PMID: 21106983
Adams et al (2007) The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med. 204(3) 571-582 PMID: 17339406
Manufactured in: United Kingdom Fibrinogen b43-63 Human is derived from Fibrinogen, which is a large plasma glycoprotein with a complex structure, and one of the most abundant proteins in blood. Fibrinogen is important in fibrin clot formation, haemostasis, and inflammatory responses. Increased plasma fibrinogen indicates a proinflammatory state and is a risk factor for vascular inflammatory diseases including hypertension and atherosclerosis. Fibrinogen cleavage products act as inflammatory activators in the pathophysiology of allergic asthma.
The conversion of monomeric fibrinogen into polymeric fibrin is mediated by thrombin, which binds to fibrinogen and catalyses cleavage of fibrinopeptide A (FpA) and fibrinopeptide B (FpB). Fibrinopeptide B is protected from modifications such as carbamylation by pyroglutamination of the N-terminal amino acid.